MENLO PARK, Calif.--(BUSINESS WIRE)--May 6, 2026--

Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor.

Mr. Walbert brings more than three decades of biopharmaceutical leadership experience and currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA®, as well as at G.D. Searle & Company, Merck & Co., and Wyeth.

“Patient Square Capital has built a highly differentiated platform and a strong record of partnering with management teams to create enduring value in health care,” said Tim Walbert. “I’m pleased to join the firm as a Senior Advisor and look forward to contributing my experience in support of the team and its portfolio companies as they advance innovations that improve patient outcomes.”

“Tim is an extremely accomplished leader and business builder with a proven history of delivering impactful therapies to patients and creating significant long-term value,” said Jim Momtazee, Managing Partner of Patient Square Capital. “We have known Tim for a long time and believe that his depth of experience will be an exceptional resource to our team and our portfolio companies as we expand our investment activities in the therapeutics sector.”

Mr. Walbert currently serves on the boards of several public and private companies, including Mirum Pharmaceuticals, Sagimet Biosciences, BioMarin Pharmaceutical, Odyssey Therapeutics, Cour Pharmaceuticals, Catalent, Crystalys Therapeutics, and Latigo Biotherapeutics, where he serves as Chairman. His prior board experience includes Aurinia Pharmaceuticals, Exicure (Chairman), Assertio (Chairman), Raptor Pharmaceutical Corp., Century Therapeutics, XOMA Corporation, and Sucampo Pharmaceuticals. Mr. Walbert earned a Bachelor of Arts in Business from Muhlenberg College.

About Patient Square Capital

Patient Square Capital is a dedicated health care investment firm with over $18 billion in assets under management. The firm aims to achieve strong investment returns by partnering with growth-oriented companies and top-tier management teams whose products, services, and technologies improve health. Patient Square utilizes deep industry expertise, a broad network of relationships, and a partnership approach to make investments in companies that will grow and thrive. Patient Square invests in businesses that strive to improve patient lives, strengthen communities, and create a healthier world. For more information, visit www.patientsquarecapital.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260506009468/en/

CONTACT: Prosek Partners

pro-PatientSquareCapital@prosek.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: GENERAL HEALTH FINANCE HEALTH PROFESSIONAL SERVICES ASSET MANAGEMENT

SOURCE: Patient Square Capital

Copyright Business Wire 2026.

PUB: 05/06/2026 08:00 AM/DISC: 05/06/2026 08:01 AM

http://www.businesswire.com/news/home/20260506009468/en